Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
20 pending office actions • 16 art units • 19 examiners • 0 of 20 (0%) have an AI response strategy ready • 22 patents granted in the last 365 days
The Scripps Research Institute currently faces 21 pending office actions within the Biotechnology & Pharmaceuticals technology area. The portfolio shows dispersion, with 20 distinct examiners and 17 distinct art units involved in the prosecution process. This variety indicates that the institute's research covers a spectrum of specialized topics within the biotechnology sector, requiring engagement with many different USPTO divisions.
The busiest examiner, DRISCOLL, LORA E BARNHART, is responsible for 2 pending actions, which is the highest concentration for any single examiner in this set. Given that 21 pending office actions are spread across 20 distinct examiners, the majority of cases are being handled by unique individuals. This lack of examiner overlap, combined with the presence of 17 distinct art units, suggests that prosecution strategies must be tailored to each application rather than relying on trends from a single examiner or art unit.
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (5%) |
| §103 only | 3 (15%) |
| §102 only | 3 (15%) |
| §112 only | 2 (10%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 4 (20%) |
| Multi-statute (no §101) | 6 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, LORA E BARNHART | 2 | 32.0% | +20.0% |
| TSAY, MARSHA M | 1 | 45.7% | +52.7% |
| SCHMIDT, IZABELA MARIA | 1 | 65.3% | +42.5% |
| BUCCINI, MICHELLE CALLAHAN | 1 | — | — |
| JONES, CHRISTINE MICHELLE | 1 | 0.0% | +0.0% |
| NEAGU, IRINA | 1 | 46.8% | +57.3% |
| LEE, ANDREW P | 1 | 48.3% | +23.1% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 59.2% | +42.1% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18327110 | ENGINEERED CELLS AND METHODS OF USE | KELLY, ROBERT M | 2d overdue |
| 18550500 | ANTIVIRAL PRODRUGS OF ETV AND FORMULATIONS THEREOF | DEKARSKE, MADELINE MCGUIRE | 33d |
| 17923171 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | SCHACHERMEYER, SAMANTHA LYNN | 65d |
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | LEE, ANDREW P | 83d |
| 18423804 | Methods, Systems, and Compositions for Diagnosing Transplant Rejection | JONES, CHRISTINE MICHELLE | — |
| 18517049 | PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME | NEAGU, IRINA | — |
| 18548635 | HETEROBIFUNCTIONAL COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION AND METHODS FOR THEIR USE | CHANDRAKUMAR, NIZAL S | — |
| 18546217 | SMALL MOLECULE ACTIVATORS OF YAP TRANSCRIPTIONAL ACTIVITY FOR REGENERATIVE ORGAN REPAIR | BRAUN, MADELINE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18504724 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | ROBINSON, MIKHAIL O'DONNEL | 26d overdue |
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | LEE, ANDREW P | 83d |
| 19083131 | REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | DRISCOLL, LORA E BARNHART | — |
| 18917399 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | TSAY, MARSHA M | — |
| 18810305 | REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | DRISCOLL, LORA E BARNHART | — |
| 18627081 | NOVEL KAPPA OPIOID LIGANDS | SCHMIDT, IZABELA MARIA | — |
| 18517049 | PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME | NEAGU, IRINA | — |
| 18548635 | HETEROBIFUNCTIONAL COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION AND METHODS FOR THEIR USE | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 3991 | 2 |
| 1627 | 2 |
| 1621 | 1 |
| 1682 | 1 |
| 1629 | 1 |
| 1691 | 1 |
| 1622 | 1 |
| 1625 | 1 |
| 1624 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19083131 | REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | DRISCOLL, LORA E BARNHART | 3991 | §112DPOther | Non-Final OA | — | Pending | Mar 18, 2025 |
| 18917399 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | TSAY, MARSHA M | — | §102§103§112DP | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18810305 | REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | DRISCOLL, LORA E BARNHART | 3991 | §112DPOther | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18627081 | NOVEL KAPPA OPIOID LIGANDS | SCHMIDT, IZABELA MARIA | 1621 | DP | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18554340 | NOVEL THERAPIES WITH ENGINEERED EFFECTOR CELLS | BUCCINI, MICHELLE CALLAHAN | — | §102§103§112DP | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18423804 | Methods, Systems, and Compositions for Diagnosing Transplant Rejection | JONES, CHRISTINE MICHELLE | 1682 | §101§103§112DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18517049 | PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME | NEAGU, IRINA | 1629 | §102§103 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | LEE, ANDREW P | 1691 | §102§103 | Non-Final OA | 83d | Pending | Nov 08, 2023 |
| 18504724 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §102 | Non-Final OA | 26d overdue | Pending | Nov 08, 2023 |
| 18550500 | ANTIVIRAL PRODRUGS OF ETV AND FORMULATIONS THEREOF | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Final Rejection | 33d | Pending | Sep 14, 2023 |
| 18548635 | HETEROBIFUNCTIONAL COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION AND METHODS FOR THEIR USE | CHANDRAKUMAR, NIZAL S | 1625 | §103§112 | Final Rejection | — | Pending | Sep 01, 2023 |
| 18546217 | SMALL MOLECULE ACTIVATORS OF YAP TRANSCRIPTIONAL ACTIVITY FOR REGENERATIVE ORGAN REPAIR | BRAUN, MADELINE E | 1624 | §103§112 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18327110 | ENGINEERED CELLS AND METHODS OF USE | KELLY, ROBERT M | 1638 | §102§112Other | Non-Final OA | 2d overdue | Pending | Jun 01, 2023 |
| 18305292 | COILED COIL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF | NATARAJAN, MEERA | 1643 | §102 | Non-Final OA | — | Pending | Apr 21, 2023 |
| 18304993 | REVERSE TRANSCRIPTION OF POLYNUCLEOTIDES COMPRISING UNNATURAL NUCLEOTIDES | FLINDERS, JEREMY C | 1684 | §112 | Final Rejection | 10d overdue | Pending | Apr 21, 2023 |
| 17923171 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §102§103 | Non-Final OA | 65d | Pending | Nov 03, 2022 |
| 17918448 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | REYNOLDS, FRED H | 1658 | §103Other | Final Rejection | 30d overdue | Pending | Oct 12, 2022 |
| 17826660 | SULFUR (VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF | OTTON, ALICIA L | 1699 | §102 | Final Rejection | — | Pending | May 27, 2022 |
| 17716848 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | SHIN, DANA H | 1635 | §103Other | Final Rejection | 8d overdue | Pending | Apr 08, 2022 |
| 17753139 | BICYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | HSU, GRACE CHING | 1627 | §112 | Non-Final OA | — | Pending | Feb 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial